NCT05559242View on ClinicalTrials.gov

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

July 31, 2023

Conditions
Liver Dysfunction
Interventions
DRUG

Anlotinib Hydrochloride Capsule

Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor

Trial Locations (2)

40010

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

410006

Hunan Cancer Hospital, Changsha

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY